Interventionalists don’t often order a CXR ahead of time, but when it’s already been done, some find the added info useful.

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

Cardiovascular imaging, which continues to evolve alongside interventions and other technologies, made notable strides in the ...

Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.

Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.

New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...